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Objectives: This study aimed to: (i) analyse the antibiotic susceptibility testing (AST) profiles of extended spec-
trum b-lactamase (ESBL)- and AmpC b-lactamase-producing clinical Enterobacteriaceae isolates applying
EUCAST 2013 AST guidelines; and (ii) evaluate discrepancies in AST profiles according to EUCAST 2010 guide-
lines, EUCAST 2013 guidelines, CLSI 2009 guidelines and CLSI 2013 guidelines.
Methods: The 195 ESBL- and/or AmpC b-lactamase-producing Enterobacteriaceae isolates used in this study
were systematically characterized by disc diffusion AST interpreted according to the 2013 guidelines of
EUCAST and CLSI, the EUCAST 2010 guidelines and the CLSI 2009 guidelines.
Results: Individual cephalosporin AST patterns according to EUCAST 2013 guidelines were described for individ-
ual ESBL and AmpC b-lactamase genotypes. Significant differences in the susceptibility rates of important
cephalosporins such as cefepime, ceftazidime and cefotaxime applying EUCAST 2013 and CLSI 2013 AST guide-
lines were demonstrated for ESBL- and AmpC b-lactamase-producing isolates.
Conclusions: The confirmation of ESBL and/or AmpC b-lactamase production can support the selection of an
adequate antibiotic drug therapy. Despite a harmonized CLSI and EUCAST ‘report as found’ strategy for cepha-
losporins and ESBL-producing isolates, AST interpretation according to the CLSI 2013 and EUCAST 2013 guide-
lines shows significant differences in susceptibility rates for mainstay cephalosporins such as cefepime,
ceftazidime and cefotaxime. Thus, further harmonization of clinical breakpoints is warranted.
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Introduction
Extended-spectrum b-lactamase (ESBL)- and AmpC b-lactamase
(AmpC)-producing strains of Escherichia coli, Klebsiella pneumo-
niae and Enterobacter cloacae are increasingly reported world-
wide.1,2 ESBL- and AmpC-producing isolates are able to cause
life-threatening infections with a significant impact on morbidity,
mortality and healthcare-associated costs.3 – 6 The ESBL classes
that are most frequently encountered in the clinical laboratory
are types TEM, SHV and CTX-M.7 Currently, over 100 SHV ESBLs,
150 TEM ESBL types and90 CTX-M variants have been described.
CTX-M-producing E. coli has become the most prevalent ESBL type
in Europe and North America.8,9 In addition to ESBLs, Enterobac-
teriaceae can acquire plasmid-encoded ampC genes (pAmpC) as
an important resistance mechanism against b-lactams.10 E. coli
possesses a chromosomal ampC gene, which is regulated differ-
ently from other Enterobacteriaceae. ampC expression in E. coli is
constitutive at low levels due to a weak promoter and a strong at-
tenuator.11 Mutations in the promoter region leading to ampC
overexpression have been described.12
EUCAST and CLSI recently published new antimicrobial sus-
ceptibility testing (AST) guidelines that constitute a paradigm
change in the interpretation and reporting of AST for ESBL- and
AmpC-producing isolates and penicillins, cephalosporins and
monobactams.13,14 CLSI also changed its AST guidelines from
the 2009 to the 2013 version, but significant differences in
terms of the AST categorization of Enterobacteriaceae remain
in the EUCAST guidelines.15,16 Until 2009, the two institutions
recommended either reporting in vitro susceptible and inter-
mediate AST results for penicillins, cephalosporins and monobac-
tams in ESBL-producing isolates as resistant (CLSI) or modifying
the interpretation from susceptible to intermediate and from
intermediate to resistant (EUCAST).15,17 Such editing of in vitro
AST results is no longer recommended.14,16 These changes
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were accompanied by significantly higher cephalosporin zone
diameter clinical breakpoints (CBPs) in EUCAST 2013 compared
with CLSI 2009 and, in part, EUCAST 2010. Higher EUCAST
CBPs were, in part, adopted by CLSI in its 2010 to 2013
guidelines.13,15,16,18
Data systematically describing the AST profiles of ESBL- and
AmpC-producing Enterobacteriaceae isolates are of significant
interest as antibiotic therapy for ESBL- and AmpC-producing iso-
lates that are categorized as susceptible to cephalosporins, such
as cefepime, cefotaxime, ceftazidime and ceftriaxone, is now
allowed by EUCAST and CLSI. We determined here the AST pat-
terns of a well-defined set of clinical isolates of ESBL- and AmpC-
producing Enterobacteriaceae according to the former and
revised versions of the EUCAST and CLSI guidelines.
Methods
Clinical isolates
This study comprised 195 ESBL- and/or AmpC-producing non-duplicate
Enterobacteriaceae clinical isolates (i.e. one isolate per patient and
species) originating from the University Hospital of Zurich from 2009
until 2012 (Table 1). No clonal outbreak strains were detected by PFGE
(data not shown). Isolates had been characterized for the production
of an ESBL and/or an AmpC in previous studies.19,20
Susceptibility testing
Disc diffusion AST was carried out on Mueller–Hinton agar (Becton Dick-
inson, Franklin Lakes, NJ, USA) using overnight cultures with a turbidity
equivalent to that of a 0.5 McFarland standard followed by incubation
at 358C for 16–18 h. Antibiotic discs (i2a, Montpellier, France) were
used. Results were interpreted according to the EUCAST 2010, EUCAST
2013, CLSI 2009 and CLSI 2013 guidelines.13,15,16,18 The CBPs for Enter-
obacteriaceae are summarized in Table S1 (available as Supplementary
data at JAC Online).
Genotypic ESBL characterization
DNA was extracted using the InstaGene Matrix (Bio-Rad, Reinach,
Switzerland) from colonies grown on sheep blood agar according to the
manufacturer’s instructions. Detection of TEM and SHV ESBLs was carried
out as described previously.21 Wild-type E. coli AF427133.1 TEM-1 and
E. coli AF148850 SHV-1 according to the database at http://www.lahey.
org/studies were used as references to compare TEM and SHVb-lactamase
sequences. CTX-M b-lactamase genes were detected by a multiplex PCR
described by Pitout et al.8 This multiplex PCR discriminates CTX-M group
1, CTX-M group 2, CTX-M group 8 and CTX-M group 9 genes.
Genotypic ampC characterization
DNA extraction from colonies grown on sheep blood agar medium using
the InstaGene Matrix (Bio-Rad) was carried out following the manufac-
turer’s instructions. Plasmid-mediated ampC genes were detected by a
multiplex PCR described by Perez-Perez and Hanson.22 This PCR detects
six plasmid-mediated ampC families. PCR amplicons were sequenced
when necessary, using the amplification primers following the protocol
described above. Sequences were analysed for homology using the
National Center for Biotechnology Information’s GenBank (http://www.
ncbi.nlm.nih.gov/).
For the analysis of ampC promoter mutations, a 271 bp fragment was
amplified using primers AB1 (5′-GATCGTTCTGCCGCTGTG-3′) and ampC2
(5′-GGGCAGCAAATGTGGAGCAA-3′).23 PCR amplicons were purified using
the QIAquick PCR Purification Kit (Qiagen, Hombrechtikon, Switzerland) fol-
lowed by cycle sequencing using the BigDye Reagent Kit (Applied Biosys-
tems, Switzerland). Sequence analysis was performed using an ABI
Prisma 3100 DNA Sequencer (Applied Biosystems, Switzerland) following
standard protocols. Sequences were analysed and edited using Lasergene
7 MegAlign software (DNASTAR Inc., USA). The ampC promoter sequences
were compared with the wild-type ampC sequence of E. coli strain ATCC
25922.
Software
All calculations were done using IBM SPSS version 20 (IBM Corporation,
Armonk, NY, USA) and Microsoft Excel 2010 (Microsoft Corporation,
Redmond, WA, USA). To test for the statistical significance of categoriza-
tion differences, Wilcoxon’s signed-rank test and Friedman’s x2 test were
used.
Results
b-Lactam AST profiles according to EUCAST 2013
guidelines
Resistance rates to amoxicillin/clavulanic acid were significantly
higher in AmpC-producing isolates compared with ESBL-producing
isolates (e.g. resistance rates of 94.1% and 78.6%, P¼0.000, for
pAmpCs and ampC promoter mutations in E. coli, respectively;
Table 1. ESBL and/or AmpC genotypes of the Enterobacteriaceae isolates included in the study
Species Total isolates (n)
ESBL genotypes
(n¼150) AmpC genotypes (n¼32) ESBLa combined with AmpC (n¼13)
CTX-M SHV TEM pAmpC promoter mutationb pAmpC promoter mutationb chromosomal AmpC
E. coli 159 117 9 1 17 14 1 — —
K. pneumoniae 25 21 2 0 1 — 1 — —
E. cloacae 11 0 0 0 — — — — 11
Total 195 138 11 1 18 14 2 — 11
aESBL and AmpC genotypes comprised nine E. cloacae CTX-M (combined with the natural chromosomal AmpC of E. cloacae), two E. cloacae SHV
(combined with the natural chromosomal AmpC of E. cloacae), one E. coli SHV-ESBL combined with DHA-type pAmpC, and one K. pneumoniae
CTX-M combined with DHA-type pAmpC.
bApplies to E. coli isolates only. Promoter mutation of the chromosomal ampC in E. coli, which results in overexpression of AmpC.
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Table 2. Resistance profiles of E. cloacae, E. coli and K. pneumoniae isolates applying EUCAST 2013 AST guidelines to ESBL- and AmpC-producing
isolates
E. coli
Drug/interpretation (%)
E. cloacae
CTX-M (n¼9) CTX-M (n¼117) SHV (n¼9) pAmpC (n¼17)
ampC promoter
mutationa (n¼14)
K. pneumoniae
CTX-M (n¼21)
Ampicillin R 100 100 100 100
I NR — — — — NR
S 0 0 0 0
Amoxicillin/clavulanic acid R 43.6 11.1 94.1 78.6 61.9
I NR — — — — —
S 56.4 88.9 5.9 21.4 38.1
Piperacillin/tazobactam R 36.3 13.7 11.1 29.4 7.1 28.6
I 27.3 13.7 0 29.4 14.3 9.5
S 36.4 72.6 88.9 41.2 78.6 61.9
Cefuroxime R 100 97.4 33.3 82.4 35.7 100
I — 0 0 0 0 —
S 0 2.6 66.7 17.6 64.3 0
Cefoxitin R 6.8 11.1 94.1 85.7 33.3
I NR — — — — —
S 93.2 88.9 5.9 14.3 66.7
Cefpodoxime R 100 97.4 88.9 100 92.9 100
I — — — — — —
S 0 2.6 11.1 0 7.1 0
Cefotaxime R 100 93.2 22.2 88.2 21.4 100
I 0 3.4 44.4 0 14.3 0
S 0 3.4 33.3 11.8 64.3 0
Ceftazidime R 81.8 61.5 77.8 94.1 42.9 90.5
I 0 6.0 0 0 14.3 0
S 18.2 32.5 22.2 5.9 42.9 9.5
Ceftriaxone R 100 94.0 33.3 94.1 7.1 100
I 0 3.4 33.3 0 14.3 0
S 0 2.6 33.3 5.9 78.6 0
Cefepime R 63.6 69.2 0 11.8 0 81.0
I 0 10.3 11.1 0 0 9.5
S 36.4 20.5 88.9 88.2 100 9.5
Ertapenem R 18.1 0 0 0 0 4.8
I 36.4 0.9 0 5.9 0 9.5
S 45.5 99.1 100 94.1 100 85.7
Imipenem R 0 0 0 0 0 0
I 0 0 0 0 0 0
S 100 100 100 100 100 100
Meropenem R 0 0 0 0 0 0
I 0 0 0 0 0 0
S 100 100 100 100 100 100
R, resistant; I, intermediate; S, susceptible; NR, natural resistance.
aPromoter regions of the chromosomal ampC were analysed for mutations resulting in overexpression only when a pAmpC was not detected.
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Table 2). Amoxicillin/clavulanic acid resistance rates in ESBL-
producing E. coli isolates were significantly higher for CTX-M
ESBLs (43.6%, P¼0.016) compared with SHV ESBLs (11.1%). The
amoxicillin/clavulanic acid resistance rate of CTX-M-containing
isolates was higher for K. pneumoniae than for E. coli (61.9%
versus 43.6%, P¼0.121; Table 2). Piperacillin/tazobactam
showed a comparable susceptibility pattern to amoxicillin/clavula-
nic acid with one exception: the elevated production of AmpC
mediated by promoter mutation(s) in E. coli resulted in a relatively
low resistance rate to piperacillin/tazobactam of 7.1% (Table 2).
Resistance to cefotaxime, ceftriaxone and cefepime was signifi-
cantly more common in CTX-M- and pAmpC-producing isolates
compared with E. coli ampC promoter mutations (P≤0.05) and
SHV ESBLs (P≤0.05). Resistance to ceftazidime was comparably
more common in SHV ESBLs and E. coli ampC mutations (77.8%
and 42.9%, respectively; Table 2). CTX-M producing K. pneumoniae
isolates displayed significantly higher resistance rates for ceftazi-
dime and cefoxitin compared with CTX-M-producing E. coli
(90.5% versus 61.5%, P¼0.034, and 33.3% versus 6.8%,
P¼0.000; Table 2).
Carbapenems remained active against ESBL- and AmpC-
producing isolates with two exceptions: susceptibility rates to erta-
penem were significantly lower in K. pneumoniae and E. cloacae
producing CTX-M (85.7%, P¼0.002, and 45.5%, P¼0.000)
compared with CTX-M-producing E. coli (99.1%; Table 2). In add-
ition, ertapenem susceptibility was slightly decreased in pAmpC-
producing E. coli isolates (94.1%; Table 2).
Comparison of b-lactam AST profiles of ESBL- and
AmpC-producing isolates according to CLSI 2009, CLSI
2013, EUCAST 2010 and EUCAST 2013 guidelines
The amoxicillin/clavulanic acid susceptibility rates of ESBL-
producing isolates were similar when applying the EUCAST
2013, CLSI 2009 and CLSI 2013 guidelines (Table 3). In contrast,
the EUCAST 2010 susceptibility rate was significantly higher
(90.7%, P¼0.000). Piperacillin/tazobactam susceptibility rates
according to EUCAST 2010 and 2013 were slightly higher for
ESBL-producing isolates compared with the CLSI 2009/2013
guidelines (78.0% and 72.0% versus 64.0%, P¼0.165), but
lower for AmpC-producing isolates and EUCAST 2013 as com-
pared with EUCAST 2010 and CLSI 2009/2013 (56.2% versus
78.1% and 71.9%, respectively, P≤0.052; Table 3).
Various patterns of susceptibility to cephalosporins were
detected applying the EUCAST 2010, EUCAST 2013, CLSI 2009
and CLSI 2013 guidelines: similar rates of susceptibility were
found for cefuroxime and cefpodoxime for both ESBL- and AmpC-
producing isolates comparing all guideline versions (Table 3).
EUCAST 2010 and 2013 did not significantly differ in terms of ceph-
alosporin categorization except for the cefepime resistance rates
of ESBL producers, which were significantly higher applying the
2013 version (40.7% versus 66.0%, P¼0.021). Significantly lower
susceptibility rates were found when applying EUCAST 2010 and
2013 compared with CLSI 2009 and CLSI 2013 for AmpC-
producing isolates and cefotaxime and ceftazidime (P≤0.001),
and for ESBL-producing isolates and cefepime (P¼0.000,
Table 3). ESBL-producing isolates had significantly different sus-
ceptibility rates to ceftazidime when comparing EUCAST 2010
and EUCAST 2013 with CLSI 2009 and CLSI 2013 (32.0%, 28.0%,
54.0% and 38.7%, respectively, P¼0.000). The ceftriaxone
diameter CBPs are equal in EUCAST 2010/2013 and CLSI 2013
compared with CLSI 2009, resulting in significantly lower ceftriax-
one susceptibility rates for ESBL-positive, AmpC-positive and both
ESBL- and AmpC-positive isolates [CLSI 2009 versus EUCAST 2010/
2013 and CLSI 2013: 52.0% versus 4.0% (P¼0.000), 46.9% versus
37.5% (P¼0.004) and 23.1% versus 0% (P¼0.038) for ESBL-
positive, AmpC-positive and both ESBL- and AmpC-positive iso-
lates, respectively; Table 3].
Similar rates of susceptibility were demonstrated for the car-
bapenems with both ESBL- and AmpC-producing isolates. For
ESBL- and AmpC-co-producing isolates, ertapenem susceptibility
rates applying the EUCAST 2013 guidelines (46.2%) were signifi-
cantly lower than for the CLSI 2009 (92.3%, P¼0.014) and CLSI
2013 (76.9%, P¼0.014) categorizations.
Discussion
Since implementation of their 2010 AST guidelines EUCAST and
CLSI recommend reporting AST results for ESBL-producing Enter-
obacteriaceae to penicillins and cephalosporins ‘as found’ in
vitro, i.e. results are no longer edited to intermediate and/or re-
sistant, if an ESBL is present.13,16 The treatment of ESBL-
producing isolates with cephalosporins is allowed depending on
the AST categorization. EUCAST 2013 and CLSI 2013 aim to
assure the correct treatment recommendations by higher zone
diameter breakpoints compared with CLSI 2009 and, partly,
EUCAST 2010, classifying more isolates as resistant. This particu-
larly accounts for newer cephalosporins, such as cefpodoxime,
cefotaxime, ceftazidime, ceftriaxone (EUCAST and CLSI) and
cefepime (EUCAST).13,15,16,18 Using cephalosporins for ESBL treat-
ment could result in a lower selection pressure on reserve drugs
such as the carbapenems. However, few data are available
showing antibiotic susceptibility patterns for defined populations
of ESBL-producing isolates according to revised EUCAST and CLSI
guidelines.24 The same accounts for the increasing number of
AmpC-producing isolates.
Testing for the presence of an ESBL is considered useful for
epidemiological purposes by CLSI and EUCAST.13,16 Nevertheless,
it remains controversial whether the exclusive presence of a
certain resistance mechanism, e.g. ESBL or AmpC, should be con-
sidered in the selection of a calculated antibiotic drug therapy
(interpretative reading).25,26
This study describes various resistance patterns for individual
ESBL and AmpC genotype/species combinations if EUCAST 2013
CBPs are applied (Table 2). Low rates of susceptibility to cefpodox-
ime, cefotaxime and ceftriaxone were found for CTX-M-type ESBL-
producing isolates (0%–3.4%; Table 2), whereas ceftazidime and
cefepime were categorized as susceptible in 9.5%–32.5% and
9.5%–36.4% of CTX-M-positive isolates, respectively, which is in
concordance with other studies.27 For pAmpC-positive E. coli iso-
lates, susceptibility rates varied from 0% in the case of cefpodox-
ime up to 88.2% for cefepime, while E. coli isolates with ampC
promoter mutations generally displayed higher levels of suscepti-
bility to newer cephalosporins except for cefpodoxime (42.9% to
100%; Table 2). Our results underline that different b-lactamase
genotypes produce distinct phenotypic AST patterns. ESBL and
AmpC co-expression can even lead to non-susceptibility to
carbapenems, particularly in the case of ertapenem (see, for
b-Lactam AST profiles of ESBL and AmpC producers according to EUCAST and CLSI
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Table 3. Comparison of antibiotic susceptibility profiles of ESBL- and AmpC-producing Enterobacteriaceae isolates applying the CLSI 2009, CLSI 2013, EUCAST 2010
and EUCAST 2013 AST guidelines
ESBL-producing isolatesc (n¼150) AmpC-producing isolates (n¼32)
ESBL- and AmpC-producing isolatesa,c
(n¼13)
Drug/interpretation (%)
CLSI
2009
CLSI
2013
EUCAST
2010
EUCAST
2013
CLSI
2009
CLSI
2013
EUCAST
2010
EUCAST
2013
CLSI
2009
CLSI
2013
EUCAST
2010
EUCAST
2013
Ampicillin R 100 100 100 100 100 100 100 100 100 100 100 100
I 0 0 — — 0 0 — — 0 0 — —
S 0 0 0 0 0 0 0 0 0 0 0 0
Amoxicillin/clavulanic acid R 26.0 26.0 9.3 43.3 84.4 84.4 81.2 87.5 100 100 92.3 100
I 23.3 23.3 — — 12.5 12.5 — — 0 0 — —
S 50.7 50.7 90.7 56.7 3.1 3.1 18.8 12.5 0 0 7.7 0
Piperacillin/tazobactamb R 20 20 9.3 15.3 15.6 15.6 15.6 21.9 46.2 46.2 46.2 46.2
I 16.0 16.0 12.7 12.7 12.5 12.5 6.3 21.9 15.4 15.4 15.4 23.0
S 64.0 64.0 78.0 72.0 71.9 71.9 78.1 56.2 38.4 38.4 38.4 30.8
Cefuroxime R 91.3 91.3 93.3 93.3 43.8 43.8 62.5 62.5 100 100 100 100
I 2.0 2.0 — — 18.8 18.8 — — 0 0 — —
S 6.7 6.7 6.7 6.7 37.5 37.5 37.5 37.5 0 0 0 0
Cefoxitin R 2.7 2.7 — 12.0 75.0 75.0 — 90.6 100 100 — 100
I 8.0 8.0 — — 9.4 9.4 — — 0 0 — —
S 89.3 89.3 — 88.0 15.6 15.6 — 9.4 0 0 — 0
Cefpodoxime R 96.7 96.7 97.3 97.3 96.9 96.9 96.9 96.9 100 100 100 100
I 0.7 0.7 — — 0 0 — — 0 0 — —
S 2.7 2.7 2.7 2.7 3.1 3.1 3.1 3.1 0 0 0 0
Cefotaximeb R 66.7 91.3 89.3 89.3 9.4 40.6 59.4 59.4 76.9 100 100 100
I 24.7 1.3 3.4 5.3 31.2 3.1 6.2 6.2 23.1 0 0 0
S 8.7 7.3 7.3 5.3 59.4 56.2 34.4 34.4 0 0 0 0
Ceftazidimeb R 18.7 46.0 56.0 67.3 15.6 31.2 53.1 71.9 46.2 69.2 76.9 84.6
I 27.3 15.3 12.0 4.7 15.6 3.1 15.6 6.2 23.1 15.4 7.7 0
S 54.0 38.7 32.0 28.0 68.8 65.6 31.3 21.9 30.8 15.4 15.4 15.4
Ceftriaxone R 44.7 91.3 91.3 91.3 34.4 56.2 56.2 56.2 61.5 100 100 100
I 3.3 4.7 4.7 4.7 18.8 6.2 6.2 6.2 15.4 0 0 0
S 52.0 4.0 4.0 4.0 46.9 37.5 37.5 37.5 23.1 0 0 0
Cefepime R 15.3 15.3 40.7 66.0 0 0 0 6.2 7.7 7.7 15.4 69.2
I 26.0 26.0 35.3 10.0 0 0 6.2 0 7.7 7.7 53.8 0
S 58.7 58.7 24.0 24.0 100 100 93.1 93.1 84.6 84.6 30.8 30.8
Ertapenem R 0.7 0.7 0.7 0.7 0 0 0 0 0 7.7 23.1 23.1
I 0 0 2.0 2.0 0 0 3.1 3.1 7.7 15.4 30.8 30.8
S 99.3 99.3 97.3 97.3 100 100 96.9 96.9 92.3 76.9 46.2 46.2
Imipenem R 0 0 0 0 0 0 0 0 0 0 0 0
I 0 0 0 0 0 0 0 0 0 0 0 0
S 100 100 100 100 100 100 100 100 100 100 100 100
Meropenem R 0 0 0 0 0 0 0 0 0 0 0 0
I 0 0 0 0 0 0 0 0 0 0 0 0
S 100 100 100 100 100 100 100 100 100 100 100 100
R, resistant; I, intermediate; S, susceptible.
aESBL- and AmpC-positive isolates comprised nine E. cloacae CTX-M (combined with the natural chromosomal AmpC of E. cloacae), two E. cloacae SHV
(combined with the natural chromosomal AmpC of E. cloacae), one E. coli SHV-ESBL combined with DHA-type pAmpC, and one K. pneumoniae CTX-M
combined with DHA-type pAmpC.
bFor these drugs, CLSI and EUCAST use different disc contents: ceftazidime (CLSI 30 mg/disc, EUCAST 10 mg/disc), cefotaxime (CLSI 30 mg/disc, EUCAST
5 mg/disc) and piperacillin/tazobactam (CLSI 100/10 mg/disc, EUCAST 30/6 mg/disc). All isolates were tested with both disc contents in parallel and
interpretation was carried out accordingly.
cUntil 2009, CLSI recommended editing susceptible and intermediate in vitro AST results for all penicillins and cephalosporins to ‘resistant’ for clinical
reports if the presence of an ESBL was confirmed.
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example, the decreased ertapenem susceptibility rates for CTX-M-
and pAmpC-producing isolates; Table 2). Carbapenem non-
susceptibility may be caused by ESBL and/or AmpC production
combined with a loss of outer membrane porins.28 – 30 Confirming
the presence of a certain resistance mechanism (ESBL and/or
AmpC for instance) may, therefore, still be of value in selecting
an adequate calculated antibiotic therapy, as previously sug-
gested.25,26 Systematic prospective clinical studies analysing
whether the exclusive presence of an ESBL influences clinical
outcome are largely lacking.
Equal (but low) susceptibility rates were demonstrated for cef-
triaxone due to CLSI and EUCAST harmonized CBPs (Table 3). The
most prominent difference in susceptibility rates of ESBL-
producing isolates applying EUCAST 2010/2013 and CLSI 2009/
2013 was found for cefepime (58.7% versus 24.0%, P¼0.000;
Table 3). This difference resulted from CLSI retaining low
cefepime diameter CBPs in its 2013 guidelines, whereas zone
diameter CBPs for ceftazidime and cefotaxime were significantly
increased.15,16 Furthermore, the AST interpretation in EUCAST
2010, EUCAST 2013 and CLSI 2009/2013 differed for amoxicillin/
clavulanic acid, piperacillin/tazobactam and ertapenem depend-
ing on the presence of an ESBL, an AmpC or the co-expression of
both types of b-lactamases (Table 3). Considering the harmonized
‘report as found’ strategy of the current EUCAST and CLSI AST
guidelines, such discrepancies in AST interpretation by CLSI and
EUCAST warrant a further validation of CBPs. For some drugs,
EUCAST 2013 and CLSI 2009/2013 recommend different diameter
CBPs, but equal MIC CBPs, e.g. for ampicillin, amoxicillin/clavulanic
acid and ertapenem. However, resulting differences in disc diffu-
sion susceptibility rates were statistically significant only for erta-
penem and ESBL and AmpC co-producers (46.2% versus 76.9%
for EUCAST 2013 and CLSI 2013, respectively, P¼0.014). MIC/
zone correlation data to verify whether CLSI or EUCAST disc diffu-
sion breakpoints correspond better to MIC breakpoints would be
of interest, but exceeded the capacity of this study.
A limitation of this study was the local origin of the clinical
strains. However, the predominance of CTX-M-type ESBLs as in
this study is found worldwide.9,31 The number of SHV-ESBL and
TEM-ESBL types in the present work, however, was relatively
low. Thus, further studies are needed to characterize SHV-ESBL
and TEM-ESBL AST profiles according to the new CLSI and
EUCAST guidelines.
To conclude, the CLSI 2013 and EUCAST 2013 AST guidelines
displayed significant differences in disc diffusion susceptibility
rates for important drugs such as cefepime, ceftazidime or cefo-
taxime despite harmonized reporting strategies for ESBLs (and
AmpC). Thus, further adjustment of CBPs and correlation of
CBPs with MIC data and clinical outcome studies seems
warranted.
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